A 67-year-old white female patient with metastatic breast cancer, currently taking capecitabine plus trastuzumab, presented with 2 weeks of painless reduced vision in her right eye (OD). Her breast cancer was diagnosed in 2007 as stage IA estrogen-receptor positive, progesterone-receptor negative (ER+, PR−), and human epidermal growth factor 2 (ERBB2; formerly HER2) negative, initially treated with lumpectomy plus left breast radiotherapy followed by doxorubicin, cyclophosphamide, paclitaxel, and anastrazole. In 2017, metastases were found in the lumbar spine and lung and treated with fulvestrant and palbociclib plus left brachial plexus radiotherapy. Later, progressive liver metastasis and repeat biopsy with equivocal ERBB2 testing led to treatment with capecitabine plus trastuzumab.
Izzo MC, Bronner G, Shields CL. Rapidly Progressive Vision Loss in a Patient With Breast Cancer. JAMA. Published online August 22, 2019. doi:10.1001/jama.2019.12691
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: